Characteristics that modify the effect of small-quantity lipid-based nutrient supplementation on child anemia and micronutrient status: an individual participant data meta-analysis of randomized controlled trials
Authors: Wessells K. Ryan , Arnold Charles D. , Stewart Christine P. , Prado Elizabeth L. , Abbeddou Souheila , Adu-Afarwuah Seth , Arnold Benjamin F. , Ashorn Per , Ashorn Ulla , Becquey Elodie , Brown Kenneth H. , Byrd Kendra A. , Campbell Rebecca K. , Christian Parul , Fernald Lia C.H. , Fan Yue-Mei , Galasso Emanuela , Hess Sonja Y. , Huybregts Lieven , Jorgensen Josh M. , Kiprotich Marion , Kortekangas Emma , Lartey Anna , Le Port Agnes , Leroy Jef L. , Lin Audrie , Maleta Kenneth , Matias Susana L. , Mbuya Mduduzi NN , Mridha Malay K. , Mutasa Kuda , Naser Abu Mohd. , Paul Rina R. , Okronipa Harriet , Ouédraogo Jean-Bosco , Pickering Amy J. , Rahman Mahbubur , Schulze Kerry , Smith Laura E. , Weber Ann M. , Zongrone Amanda , Dewey Kathryn G. 
Published: February 2021

ABSTRACTBackgroundSmall-quantity lipid-based nutrient supplements (SQ-LNS) have been shown to reduce the prevalence of anemia and iron deficiency among infants and young children, but effects on other micronutrients are less well known. Identifying subgroups who may experience greater benefits from SQ-LNS, or who are more likely to respond to the intervention, may facilitate the development of public health policies and programs.ObjectiveOur objective was to identify study-level and individual-level modifiers of the effect of SQ-LNS on child hematological and micronutrient status outcomes.MethodsWe conducted a two-stage meta-analysis of individual participant data from 13 randomized controlled trials of SQ-LNS provided to children 6 to 24 months of age in low- and middle-income countries (n = 15,946). Outcomes were hemoglobin (Hb), inflammation-adjusted plasma ferritin, soluble transferrin receptor, zinc, retinol and retinol binding protein (RBP), and erythrocyte zinc protoporphyrin, and respective dichotomous outcomes indicative of anemia and micronutrient deficiency. We generated study-specific estimates of SQ-LNS vs. control, including main effects and subgroup estimates for individual-level effect modifiers, and pooled the estimates using fixed-effects models. We used random effects meta-regression to examine potential study-level effect modifiers.ResultsProvision of SQ-LNS decreased the prevalence of anemia (Hb < 110 g/L) by 16% (relative reduction), iron deficiency (plasma ferritin < 12 µg/L) by 56% and iron deficiency anemia (IDA; Hb < 110 g/L and plasma ferritin < 12 µg/L) by 64%. We observed positive effects of SQ-LNS on hematological and iron status outcomes within all subgroups of the study-level and individual-level effect modifiers, but effects were larger in certain subgroups. For example, effects of SQ-LNS on anemia and iron status were greater in trials that provided SQ-LNS for > 12 months and provided 9 mg/d vs. < 9 mg iron/d, and among later-born (vs. first-born) children. There was no effect of SQ-LNS on plasma zinc or retinol, but there was a 7% increase in plasma RBP and a 56% reduction in vitamin A deficiency (RBP < 0.70 µmol/L), with little evidence of effect modification by individual-level characteristics.ConclusionsSQ-LNS provided to infants and young children 6-24 months of age can substantially reduce the prevalence of anemia, iron deficiency, and IDA across a range of individual, population and study design characteristics. Policy-makers and program planners should consider SQ-LNS within intervention packages to prevent anemia and iron deficiency. This study was registered atwww.crd.york.ac.uk/PROSPEROas CRD42020156663.